Nanomedicines for brain diseases

Published on November 29, 2018   50 min

Other Talks in the Series: Drug Delivery

Please wait while the transcript is being prepared...
Hello. I'm Giovanni Tosi. I'm an Associate Professor at the University of Modena and Reggio Emilia in the field of Pharmaceutical Sciences. I'm belonging to the Parliament of Life Science and my work is mainly devoted to nanomedicine and in particular to the application of nanomedicine in brain disease.
So, if you look at the last 10 years of nanomedicine for brain disease records, you will see that a very huge number of papers published in different international journals with skilled preclinical results mainly on therapeutics and diagnostics.
But, if you go to look how many are the nanomedicine products for brain disease markets, you will find absolutely nothing. So, it is the Death Valley of this nanomedicine approach.
So, there are many factors that will affect the marketability of nanomedicine for brain disease on marketing that are mainly dealing with safety, efficacy, GMP production, scaling up of nanomedicine, and there's a problem in economics sustainability. So, the question now is if the problem is connected with nanomedicine as nano-sized systems or the problem is connected with the targets that is the brain.
So, in my talk, I will try to go depth into some question and some take-home message that we can take off from our research in dealing with the blood-brain barrier which is the first topic and then going into topics like planning a nano-4-neuro, strategies for blood-brain barrier crossing, and some technological and pharmacological issue. Finish with some experience that has in this field. So, the first topic is the blood-brain barrier.